IN VITRO ANTICANCER ACTIVITY OF NANAZOXID DRUG AGAINST COLORECTAL CANCER CELL LINE AND ITS MOCLECULAR PATHWAYS | ||||
| Egyptian-Arab Journal of Applied Sciences and Technology | ||||
| Article 4, Volume 1, Issue 2 - Serial Number 1, November 2021, Page 29-37 PDF (910.28 K) | ||||
| Document Type: Original articles | ||||
| DOI: 10.21608/eajast.2021.89088.1000 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Nourhan Abed1; Salwa El-hallouty* 2; Emad El-Zayat3; Ahmed El-Sherief4 | ||||
| 1Department of Biotechnology, Faculty of Science, Cairo University, Cairo, Egypt | ||||
| 2Drug Bioassay-Cell Culture Laboratory, Pharmacognosy Department, National Research Center, Dokki, Giza, 12622, Egypt | ||||
| 3Department of Zoology, Faculty of Science, Cairo University, Cairo, Egypt | ||||
| 4Department of Chemistry, Faculty of Science, Cairo University, Cairo, Egypt | ||||
| Abstract | ||||
| SUMMARY Drug repurposing is gaining popularity in treatment discovery because it is a smart strategy to quickly exploit new molecular targets of a known clinically authorized drug in a variety of diseases, both existing and novel. Some early studies showed that hydroxychloroquine which has long been used for malaria, is used to reduce fever and inflammation of COVID-19 patients. Cancer is a major health issue worldwide. During the past years, some drugs are proved to be anticancer drugs as Raloxifene to treat breast cancer and Aspirin to treat colorectal cancer. According to the national cancer institute the second most killer cancer is the cancer of colon and rectum around the world. Colorectal cancer is Egypt's seventh most prevalent cancer, accounting for 3.47 % cancers. Colon cancer patients (excluding rectal cancer) were expected to number somewhat more than 3,000. Our aim in this project is to repurpose clinically used antibiotics in the Egyptian market for colorectal cancer. Anticancer efficacy of numerous antibiotic drugs was being tested by screening them in monolayer (2D).Results showed that Nanazoxid as a promising drug as anti-cancer drug especially for colorectal cancer with IC50 (0.20 μg/ml) and was tested for its selectivity index on human cell line and was subjected to molecular analysis. As a result, an antibiotic drug which is Nanazoxid proved that it could be repurposed as an anti-colorectal therapy with proper further research and development. | ||||
| Keywords | ||||
| Colorectal Cancer; Drug Repurposing; Antibiotics; human cell line; Aspirin; COVID; 19; Nanazoxid | ||||
|
Statistics Article View: 295 PDF Download: 199 |
||||
